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Abstract
Background: Despite advances in the treatment of depression, one-third of depressed patients fail to respond to
conventional antidepressant medication. There is a need for more effective treatments with fewer side effects. The
primary aim of this study was to determine whether hyperthermic baths reduce depressive symptoms in adults
with depressive disorder.
Methods: Randomized, two-arm placebo-controlled, 8-week pilot trial. Medically stable outpatients with confirmed
depressive disorder (ICD-10: F32/F33) who were moderately depressed as determined by the 17-item Hamilton
Scale for Depression (HAM-D) score ≥18 were randomly assigned to 2 hyperthermic baths (40 °C) per week for
4 weeks or a sham intervention with green light and follow-up after 4 weeks. Main outcome measure was the
change in HAM-Dtotal score from baseline (T0) to the 2-week time point (T1).
Results: A total of 36 patients were randomized (hyperthermic baths, n = 17; sham condition, n = 19). The intention-
to-treat analysis showed a significant (P = .037) difference in the change in HAM-Dtotal score with 3.14 points after 4
interventions (T1) in favour of the hyperthermic bath group compared to the placebo group.
Conclusions: This pilot study suggests that hyperthermic baths do have generalized efficacy in depressed patients.
Trial registration: DRKS00004803at drks-neu.uniklinik-freiburg.de, German Clinical Trials Register (registration date
2016-02-02), retrospectively registered.
Keywords: Depression, Hyperthermic baths, Heart rate variability, RCT
Background
Depression is the leading cause of disability worldwide,
and a major contributor to the global burden of disease,
with more than 350 million people of all ages suffering
from depression [1]. The associated economic burden is
estimated at $317 billion annually [2], and antidepres-
sant medications have become the most commonly pre-
scribed treatment in medical practice [3]. In addition,
psychiatric conditions, particularly depressive disorders,
are associated with increased prevalence of chronic
diseases and often precipitate or exacerbate these condi-
tions [4]. Depression is a known risk factor for the devel-
opment of cardiovascular disease (CVD) [5], and
patients with CVD and depression have a two to three-
fold increased risk of future cardiac events compared to
cardiac patients without depression [6].
Alterations in the autonomic nervous system have
been hypothesized to be an underlying physiological
mechanism that may partly explain these unfavorable
health outcomes among depressed persons. Such alter-
ations are believed to disturb circadian functioning,
sleep and temperature physiology [7]. Depressed persons
are found to have a reduced heart rate variability (HRV),
a well-known prognostic risk factor for CVD and
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mortality; however, it is unclear whether this is a conse-
quence of the disorder or due to antidepressant medica-
tion [8, 9]. Most depressed patients also report
disturbances in their sleep, such as difficulties in falling
asleep, waking during the night or early morning awak-
enings. Thus, sleep disturbance is an important mechan-
ism contributing to depression [7, 10]. Furthermore,
body core temperature in depressed patients is elevated
during the night; thus, change of body temperature
might influence depression [11, 12]. Despite advances in
the treatment of depression, one-third of depressed pa-
tients fail to respond to conventional antidepressant
medication [13].
Moreover, current treatments come at the cost of sig-
nificant central nervous side effects, further highlighting
the need for more effective treatments with fewer side
effects [14].
As a conclusion, there is a need for additional (non-
pharmacological) treatment of depressive patients that
positively influence cardiovascular risk factors, HRV and
quality of sleep. Evidence suggests that hyperthermic
baths (HTB) and other forms of whole body hyperthermia
(WBH) have antidepressant effects, mediated through
changes in circadian functioning and temperature physi-
ology, although the underlying mechanisms remain un-
clear [15, 16].
Results of a non-controlled HTB study with 20 depres-
sive patients showed an improvement in the 21-item
Hamilton Depression Scale [17] after five baths [18].
Furthermore, HTB (especially before bedtime) improved
sleep in healthy subjects [19–22], insomniac people [23,
24] and elderly patients with vascular dementia [25]. In
a further non-controlled study using a radiant system to
induce WBH, a single session showed a significant
reduction in the Centers for Epidemiologic Studies
Depression Scale (CES-D) [26] in 16 depressive
patients [27].
Results of these uncontrolled studies are promising;
therefore, we conducted this randomized sham-placebo-
controlled pilot study that included assessment of de-
pressive symptoms, sleep quality and HRV parameters.
Our hypotheses were 2-fold. First, we expected HTB to
lower depressive symptoms. Second, we expected this to
be mediated by improved sleep and circadian function-
ing, evoked by changes in HRV parameters.
Methods
Study design and participants
Because of the unknown effect size and in order to
evaluate the feasibility of recruitment and assessment
procedures a pilot study was conducted.
This pilot study was a single-site, parallel-group, ran-
domized controlled trial of HTB vs sham-placebo (green
light) for patients with a confirmed diagnosis of
depression according to ICD-10 (F32/F33) of at least
4 weeks duration. Recruitment via public announce-
ments took place from June 2013 until September 2013.
Eligible participants were men and women between
the ages of 18 and 65 who had been on a consistent anti-
depressant regimen or had been off antidepressant ther-
apy for at least 4 weeks prior to baseline. No changes in
antidepressant treatment were allowed during the study.
All participants were required to have a total score ≥ 18
and a score ≥ 2 on item 1 (Depressed Mood) at screening
and at baseline, assessed by the 17-item Hamilton Scale
for Depression (HAM-D). Exclusion criteria included
the presence of severe concomitant disease, epileptic dis-
orders, organic psychotic disorders, schizophrenia, hallu-
cinations, bipolar disorders, dissociative personality
disorder, suicidal thoughts, abuse of alcohol or other
drugs within the last 6 months, use of ß-blockers or cor-
ticosteroids, open wounds, heat urticaria, pregnancy, lac-
tation, aversion to hot baths and participation in clinical
trials in the 8 weeks preceding the study.
Ethics statement
Ethical approval was obtained from the local Ethics
Committee (Ethics-Commission Medical Center Univer-
sity of Freiburg; 96/13; 22.04.2013). The study was retro-
spectively registered in the German Clinical Trials
Register (DRKS) with the registration number
DRKS00004803. The study was conducted in accordance
with the Declaration of Helsinki and local laws and regu-
lations. All participants gave written informed consent.
The full study protocol can be found in Additional file 1.
Interventions
Patients were randomly assigned to receive either HTB
or green light therapy (sham condition) for 4 weeks with
2 interventions per week (8 interventions in each group).
Follow-up took place 4 weeks after the last intervention
(see Table 1). Patients were told that two promising
treatments are compared in the study.
Hyperthermic baths
The hyperthermic baths were applied as head-out-of-
water-immersion in a 40 °C pool at a spa center near
Freiburg, Germany. All the baths were conducted in the
afternoon (14:00–18:00). Five patients were able to sit in
the pool at a time. The baths were taken until the partic-
ipants noticed discomfort, the target being 30 min. Dir-
ectly after the bath, the participants were accompanied
to a nearby resting room, where they lay down on a rest-
ing lounger and were wrapped in warm blankets with 2
conventional 0.7 l hot water bottles (abdomen, thighs)
filled with boiling water for at least another 30 min to
keep the body temperature elevated. After 20–30 min in
a hyperthermic bath with a water temperature of 40 °C a
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raise in core body temperature of 1.7 °C can be expected
[28].
The following parameters were controlled and docu-
mented: water temperature in the bath, duration of bath
and resting time.
Core body temperature
Core body temperature was measured with an infrared-
ear-thermometer (Thermoscan®, Type: 6021, Braun
GmbH), before and after the bath and after resting.
Sham intervention
Participants received a sham green LED light interven-
tion (<400 Lux; <40 min) in group settings in a sitting
position at a university outpatient’s department.
Therapeutic effects can be expected for therapies at 10
000 Lux/30 min per day [29].
Outcome measures
Unblinded assessments were performed at the following
3 time points (see Table 1): before the start of HTB
treatment (T0), immediately on completion of the 2-
week treatment interval (T1), according to results that
effects are supposed to appear early, [15] and 4 weeks
after the end of treatment (T2).
The primary outcome was determined to be the
change in HAM-Dtotal score at T1 relative to T0. Second-
ary efficacy outcome measures were (1) change in
HAM-Dtotal score at T2 relative to T0 to investigate
whether immediate responses would last after treatment
discontinuation, (2) change in HAM-D subscales (T1
and T2): Insomnia as a symptom was measured by a
HAM-D subscale (range of scores 0–4) defined by the
cluster of items 4 (Early in the Night), 5 (Middle of the
Night), and 6 (Early Hours of the Morning). Low mood,
a core symptom of depression, was assessed by a HAM-
D subscale consisting of items 1 (Depressed Mood), 2
(Guilt), 3 (Suicide), 7 (Loss of Interest), and 10 (Anxiety).
Somatic complaints were measured by a HAM-D sub-
scale defined by the cluster of items 11 (Anxiety
Somatic), 12 (Gastro-intestinal Symptoms), and 13 (Gen-
eral Symptoms) [30, 31].
Heart rate variability outcome measures
Further secondary endpoints were standard HRV param-
eters, notably total heart rate variability (SDNN; stand-
ard deviation of normal-to-normal R-R intervals), low
frequency (LF), high frequency (HF), LF/HF ratio and
heart rate (HR; mBPM) during sleep (T1 and T2: 21:00-
04:00, 21:00-0:30 and 0:30-4:00). We chose these night-
time intervals because we were interested in sleep
patterns and because these measurements are supposed
to show less artefacts and influence of daily life activity.
HRV was measured with a portable high-frequency re-
corder “Medilog® AR12plus” (Schiller Medizintechnik
GmbH, Germany), with a resolution of 1000 Hz. Elec-
trodes were fixed at 5 locations (upper and lower end of
sternum, below lateral third of left clavicle, under ribs
right and left of left mamillar line). HRV analysis was
performed with the program “Medilog Darwin Version
1.13.4”.
Global judgement of efficacy and tolerability
After 4 treatments (T1) and 4 weeks after end of treat-
ment (T2), participants were asked to rate the efficacy
and tolerability of the intervention on a 5-point scale (1
indicates very good; 2, good; 3, moderate; 4, absent; 5,
worsening).
Adverse events
Adverse events (AE) were documented before and after
each treatment by two unblinded assistants.
Table 1 Diagram of the study protocol
2 weeks 2 weeks 4 weeks
Screening Baseline/Randomization After 4 interventions Follow-up
T0 T1 T2
HTB target (n)a 4 4
17-item HAM-D x x x x
Medical historyb x
HRVc x x x
Global judgement of efficacy x x
Global judgement of tolerability x x
Adverse eventsd x x x
Assessments of psychometry and heart rate variability parameters (HRV) were conducted at baseline (T0), after 2 weeks of treatment (T1), and 4 weeks after
discontinuation of treatment (T2). Note that assessments were not conducted after 4 weeks of treatment
a HTB: hyperthermic baths; temperature of bath; ear-temperature before/after bath; ear-temperature after rest; duration of bath (target 30 min); duration of rest
bDuration of depression; approved diagnosis family/consulting physician; intake of psychometric drugs no/yes; psychotherapy no/yes; psychiatric hospital stays
c Application of portable ECG for overnight measurement
d Adverse events were documented before and after each treatment
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Statistical analyses
Sample size
We calculated the sample size assuming an effect of one
standard deviation (SD) between the groups based on a
two-sided t test with an α-risk level of .05 and a statis-
tical power of 80%, requiring 17 participants per group.
With an expected dropout rate of 20%, 22 participants
per group were chosen. Because of slow recruitment and
logistical difficulties, however, the study was halted be-
fore the target sample size was attained.
Randomization and blinding
Randomization codes were computer-generated by an
independent biometric center. Allocation was performed
with opaque sealed envelopes that were randomly
chosen by the participants. Both therapies could not be
blinded. Data management and analyses were performed
blinded to treatment allocation.
Data analyses
Efficacy parameters were analyzed based on the
intention-to-treat (ITT) population, defined as all allo-
cated participants, applying the last-observation-carried-
forward approach to impute missing data. Baseline char-
acteristics were compared using 2-sided t tests for con-
tinuous data and χ2 statistics. The per-protocol (PP)
population was defined as all participants who had a
complete dataset for the relevant parameters and had
participated in at least 75% of the treatments, meaning
at least 3 of 4 treatments for T1, and at least 6 of 8 treat-
ments for T2.
Based on the fact that the HTB group was expected to
show better performance than the placebo group, we
justified 1-sided testing on the primary and secondary
outcomes of depression ratings. We report P-values with
the significance level set at P < .05 and Cohen d [32] as
effect size. Correlation analyses were used to explore as-
sociations between HAM-D scores and HRV parameters.
Secondary analyses were not adjusted for multiple com-
parisons and should therefore be regarded as descriptive
and exploratory. Where not otherwise indicated, data
are expressed as mean (SD). Statistical analyses were
performed using SPSS®, Version 22, for WindowsTM.
Results
Study population
We included and randomized 36 depressed patients
(HTB, n = 17; placebo, n = 19). Six patients (HTB, n = 3;
placebo, n = 3) discontinued treatment before T1; none
were lost to follow-up (see Fig. 1). Randomization was
balanced with respect to demographic and clinical char-
acteristics (Table 2).
Treatment effect on core body temperature
Core body temperature rose from 36.6 °C before the
baths to 39.1 °C directly after the baths (mean change
2.43 [0.4]) and maintained at 37.7 °C (mean change 1.06
[0.5]) after rest. The mean temperature of the bath was
40.2 °C (0.3). Mean duration of baths was 22.6 (3.5) min
and resting time amounted to 33.2 (6.3) min.
Primary outcome
The ITT analysis showed a significant (P = .037) differ-
ence in the change in HAM-Dtotal score with 3.14 points
after 4 interventions in favour of the HTB group com-
pared to the placebo group (see Fig. 2). This result was
confirmed by the PP analysis (P = .031) and the subscales
HAM-Dinsomnia (P = .048) and HAM-Dmood (P = .045)
showed a significant improvement compared to the pla-
cebo group (Additional file 2: Table S1). Posthoc
subgroup-analyses according to HAM-D scores quartiles
(median) revealed the greatest treatment effect in quar-
tiles 3 and 4. We found a difference of 7.88 (7.5) for
HAM-D >22 at baseline in the HTB group (n = 8) and of
1.71 (1.7) in the placebo group (n = 7) (d = 1.10; 95% CI,
0.02 to 2.19) and a difference of 12.5 (8.2) for HAM-D
>26 at baseline in the HTB group (n = 4) and of 1.66
(2.3) in the placebo group (n = 3); (d = 1.67; 95% CI,
-0.07 to 3.40).
Secondary outcomes
The positive effect of HTB treatment on depression
remained stable until 4 weeks after the intervention
without, however, reaching statistical significance
(Table 3). For results of the PP analysis, see Additional
file 2: Table S2 and Figures S1, S2.
Heart rate variability
Throughout the study, the data analysis (PP) did not
reveal significant differences in HRV parameters
between the HTB and the placebo group. Interestingly,
the improvement of sleep quality (HAM-Dinsomnia)
within 3 days of HTB treatment significantly correlated
with an increase of nocturnal pulse rate (pearson -.63;
P2-tailed = .020) and overnight drop of the parameters LF
(pearson .65; P2-tailed = .016) and total variability of HRV
(SDNN; pearson .62; P2-tailed = .024). There was no cor-
relation of these parameters in the sham condition.
Global judgement of efficacy and tolerability
The global judgement by the participants showed no sig-
nificant difference between the groups, with good to
moderate efficacy (HTB 2.6 (0.9); placebo 2.8 (1.0); P2-
tailed = .62) and tolerability (HTB 2.2 (1.1); placebo 1.6
(0.9); P2-tailed = .17) after 4 interventions and good to
moderate efficacy 4 weeks after intervention (HTB 2.8
(1.15); placebo 2.7 (1.10); P2-tailed = .84).
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Gender (female/male), n 28/8 14/3 14/5 0.70
Age (years) 47 (11.9) 44 (13.0) 49 (10.6) 0.22
BMI (kg/m2) 24 (5.2) 24 (3.9) 25 (6.3) 0.72
Duration of depression (months) 93 (85.7) 98 (92.5) 89 (82.7) 0.79
Use of psychopharmaca (%) 64 65 63 1
HAM-Dtotal score 22.36 (3.7) 23.06 (3.9) 21.74 (3.4) 0.29
HAM-Dinsomnia 3.36 (2.0) 3.35 (1.8) 3.37 (2.3) 0.98
HAM-Dmood 10.47 (2.1) 10.82 (1.8) 10.16 (2.3) 0.35
HAM-Dsomatic 3.92 (1.2) 4.00 (1.3) 3.84 (1.2) 0.71
Heart rate (21:00-04:00)b 72.77 (10.8) 73.20 (9.4) 72.39 (12.2) 0.84
HRV LF (21:00-04:00)b 490.30 (329.8) 485.70 (353.6) 494.33 (319.3) 0.94
HRV HF (21:00-04:00)b 161.94 (133.8) 156.47 (154.6) 166.72 (117.6) 0.84
HRV SDNN (21:00-04:00)b 55.14 (16.5) 55.33 (15.9) 54.97 (17.6) 0.95
Where not otherwise indicated, data are shown as mean and standard deviation (SD)
Abbreviations: HTB hyperthermic baths, BMI body mass index (calculated as weight in kilograms divided by height in meters squared)
aCalculated as comparisons of HTB and placebo, using 2-tailed t tests (continuous variables) or χ2 tests (discrete variables)
bNight-time intervals
Fig. 1 CONSORT Flow Diagram of study participants
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Adverse events
AE were reported by 21 participants, of which 12 (86%)
were assigned to the HTB group and 9 (56%) to the pla-
cebo group (Additional file 2: Table S3). No serious AE
were reported by either group. There was no significant
difference between the groups (P2-tailed = .118). Typical
AE in the HTB group were discomfort during the baths
such as dizziness, tachycardia, tingling in the extremities
and strong perspiration and thus mainly attributable to
the cardiovascular system. Additionally, patients re-
ported minor headache and nausea or a feeling of op-
pression, poorer sleep and increased sweating on the
following days. Typical AE in the sham condition were
afterimages lasting a few seconds to minutes after
application, head pressure (headache) and worse sleep
quality during the following night. AE resulted in 3
dropouts (DO) in the HTB group (DO1 weight loss,
headache, exertion the day after treatment; DO2 anxiety
at night; DO3 headache) and in 2 dropouts in the pla-
cebo group (DO1 feeling of tension; DO2 feeling of ag-
gression). One dropout in the placebo group was due to
lack of time. Compliance was good with a medium num-
ber of treatments of 7.3 (1.4) in the HTB group and of
7.8 (0.5) in the placebo group.
Discussion
The main result of this pilot study was a moderate
but significant improvement of 3.1 points in HAM-
Table 3 17-Item Hamilton Scale for Depression: Differences between baseline and T1 (after 4 interventions) and T2 (4 weeks after















b 4.35 (6.3) 1.21 (3.7) 0.037* 0.62 [-0.05-1.29] 4.82 (7.3) 3.26 (5.7) 0.238 0.24 [-0.42-0.90]
2HAM-Dinsomnia
b 0.94 (1.8) 0.16 (1.0) 0.053 0.55 [-0.11-1.22] 0.88 (1.7) 0.58 (1.8) 0.306 0.17 [-0.49-0.83]
2HAM-Dmood
b 2.35 (3.2) 0.84 (2.2) 0.054 0.55 [-0.12-1.22] 2.82 (3.8) 1.74 (2.5) 0.156 0.33 [-0.33-0.99]
2HAM-Dsomatic
b 0.59 (1.0) 0.21 (1.4) 0.182 0.31 [-0.35-0.97] 0.71 (1.4) 0.58 (1.4) 0.390 0.09 [-0.56-0.75]
Abbreviations: HTB hyperthermic baths, HAM-D Hamilton Scale for Depression
aThe intention-to-treat analysis used last-observation-carried-forward
bIndicates differences between HTB and placebo in the change from T0 to T1/T2 to each patient’s own end point for the change in depression rating
cComputed as the difference between the means, M2 – M1, divided by the pooled standard deviation, sigma (σpooled) of both groups. [95% confidence interval]





Fig. 2 Change scores in the 17-Item Hamilton Scale for Depression (HAM-D-17) from baseline (T0) in the hyperthermic bath group compared to the
placebo group (intention-to-treat population;a N = 36). T1 indicates after 2 weeks of treatment (4 hyperthermic baths (HTB) vs sham intervention with
green light (placebo); T2, 4 weeks after discontinuation of treatment (follow-up).aThe intention-to-treat analysis used last-observation-carried-forward.-
Error bars indicate standard deviation.* P = 0.037
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Dtotal score after 4 HTB treatments compared with a sham
condition. The threshold for clinical significance, as estab-
lished by the National Institute for Clinical Excellence
(NICE), was reached with a treatment-placebo difference
of 3 points on the HAM-D [33]. Cohen d was .62 (95% CI,
-0.05 to 1.29). This is larger than the effect size of anti-
depressant medication in a patient-level meta-analysis
with d = .37 [34].
In clinical trials with antidepressants, an effect size of
0.40 or higher is considered a clinically significant response
criterion [35]. The effect appears even stronger if we take
into account that the effect sizes in published trials of anti-
depressant medication are 32% higher than in unpublished
trials [36]. As in pharmacological studies, the magnitude of
the difference in HAM-D scores between the HTB and the
placebo group increases with increasing baseline depression
severity (HAM-D >22, d = 1.10; 95% CI, 0.02 to 2.19;
HAM-D >26, d = 1.67; 95% CI, -0.07 to 3.40) [34]. Surpris-
ingly, compared with the sham intervention, this did not re-
sult in a better global judgement of efficacy.
Nevertheless, these results should be interpreted with
caution. First, this was a pilot study with a small sample
size. Second, an improvement in HAM-Dtotal score does
not necessarily indicate antidepressant action [37, 38].
On the other hand, our symptom-specific subscales
show a statistically and clinically significant improve-
ment in the dimensions “mood” and “insomnia”, at least
in the PP analysis. It is a well-known fact that the HAM-
Dtotal score has it pitfalls, however, for better comparabil-
ity with other studies, we did not use the GRID-HAM-D
e.g., with better reliability and validity [39].
Regarding feasibility we did not achieve the calculated
number of 44 participants in the foreseen recruiting period,
the application of the hyperthermic baths was well toler-
ated, we saw some minor but no severe AE, dropout rate
was 18% in the HTB group and 16% in the placebo group.
The mechanism of action of HTB treatment is still un-
known, but major hypotheses of WBH involve resyn-
chronization of circadian rhythms and/or restoration of
temperature physiology, resulting e.g. in better sleep [15,
16, 18]. Hence, our results are compatible with the the-
oretical model. We assume the difference in HAM-D
scores was mainly due to an improvement in sleep qual-
ity (HAM-Dinsomnia). This is in accordance with studies
on sleep disorders in non-depressed patients [19–25].
In our study, we could not see a significant effect of
HTB on HRV. This may have been due to the small
sample size and the high variability of HRV parameters
[40]. Different effects of HTB on HRV according to age
[41] may also have influenced our results, however, the
sample size was too small to perform subgroup analyses.
These findings suggest that HTB treatment improves
sleep quality, mediated through a 2.4 °C increase in core
body temperature. Minor and medium adverse effects
were encountered these mainly being discomfort and
orthostatic problems arising during or directly after the
baths but also disturbed sleep in some patients the night
after the intervention. Besides these transient effects,
HTB treatment was well tolerated.
Our results are in line with a previously published
controlled study. After 2 weeks, a single session of WBH
using a radiant system, with a maximum core body
temperature of 38.9 °C, resulted in a decrease in HAM-
D of 6 points, compared to a sham intervention [42].
This might indicate that different hyperthermia applica-
tions, fewer hyperthermic sessions, as well as lower core
body or slightly higher skin temperatures give better
results.
Strengths and limitations
The strengths of our study are the randomized, placebo-
controlled design, the use of standardized baths, the good
control of temperature, the clinically relevant increase in
core body temperature, duration of hyperthermia of about
60 min and the relatively low number of dropouts.
Several limitations should be discussed. First, because
of the small sample size, the study had limited power to
detect clinically significant differences between the treat-
ment conditions, especially in subgroup analyses. Sec-
ond, the absence of blinding of treatment conditions,
which is inherent and inevitable, and of outcome mea-
sures (only data management and statistical analyses
were performed blinded). Third, the monitoring of de-
pressive symptoms was limited to T1 and T2.
Generalizability
Although external validity may be restricted due to the
population selected to participate in clinical studies, the
population studied here can be regarded as representa-
tive of routine clinical practice, including patients with
and without antidepressant medication [43]. Contraindi-
cations to HTB are still not well defined. Severe con-
comitant diseases, esp. cardiovascular, should be omitted
especially in the elderly.
There is no hint that HTB treatments are less effective
in combination with other pharmacological or non-
pharmacological treatments, because we did not see a
difference in outcome according to subgroups with or
without antidepressant medication. There is also no the-
oretical reason that would compromise a combination
with other non-pharmacological treatments.
Conclusions
In conclusion, this pilot study demonstrates effects of
HTB on depressive symptoms and sleep quality in
depressed patients, especially in severely depressed
patients, with fast onset of treatment success after 4
treatments in 2 weeks, without severe AE and with
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relatively good acceptance and tolerability. With HTB
treatment, the core body temperature can be raised rap-
idly and with clinically relevant effect (2.4 °C in 20 min).
Further evaluation in rigorously designed clinical stud-
ies will be necessary to validate the impact of HTB treat-
ment on depressive disorders. Studies should preferably
explore mediators and moderators of response.
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